Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. [electronic resource]
Producer: 20081126Description: 7956-65 p. digitalISSN:- 1538-7445
- Adenocarcinoma -- drug therapy
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Cell Proliferation -- drug effects
- Chick Embryo
- Drug Resistance, Neoplasm -- drug effects
- Drug Synergism
- Female
- Genes, bcl-2 -- physiology
- Humans
- Mice
- Mice, Nude
- Pancreatic Neoplasms -- drug therapy
- RNA, Small Interfering -- administration & dosage
- TNF-Related Apoptosis-Inducing Ligand -- administration & dosage
- Tumor Cells, Cultured
- X-Linked Inhibitor of Apoptosis Protein -- antagonists & inhibitors
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.